TANGO THERAPEUTICS INC. - COMMON STOCK

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in Upcoming Investor Conferences

01 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in Upcoming Investor Conferences

02 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates

25 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

10 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in Upcoming Investor Conferences

07 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

19 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

05 Oct 2022 08:10:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

10 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

02 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

27 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

08 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

11 May 2022 07:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022

09 May 2022 07:00:02 By Nasdaq GlobeNewswire

Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

28 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting

08 Mar 2022 16:57:30 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress

03 Mar 2022 09:41:35 By Nasdaq GlobeNewswire

Tango Therapeutics to Participate in Upcoming Investor Conferences

02 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates

24 Jan 2022 07:00:01 By Nasdaq GlobeNewswire